title: Successful use of etanercept for the treatment of Reiter's syndrome: a case report and review of the literature.
abstract: The treatment of severe and refractory cases of reactive arthritis is not well defined. There is a limited data about the use of tumor necrosis factor-α (TNF-α) blockers in reactive arthritis. Herein is a description of a patient with severe case of Chlamydia trachomatis-related reactive arthritis that was refractory to nonsteroidal anti-inflammatory drugs, sulfasalazine, prednisone, and methotrexate and was successfully treated with etanercept.
authors.affiliation: University of Missouri-Kansas City, Kansas City, MO, USA. edreesa@umkc.edu
authors.forename: Amr
authors.initials: A
authors.lastname: Edrees
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000188:drug therapy* / Q000382:microbiology; D002690:Chlamydia Infections / Q000150:complications; D002692:Chlamydia trachomatis; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept